Rhythm CEO Keith Gottesdiener hits the exit; Takeda sets up an AI discovery program at MIT
→ Rhythm Pharmaceuticals $RYTM CEO Keith Gottesdiener is planning to stay at the helm until the biotech completes its new drug application, and then head out. He says it’s the right time to hand over the reins and the company plans to organize a search for his replacement. His last task should be done by the end of Q1. “For the more than eight years that I have been CEO, it has been an honor to lead the talented Rhythm team, and I am immensely proud of our work to advance setmelanotide and bolster the understanding of rare genetic disorders of obesity,” said Gottesdiener in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.